Squarepoint
INFI

Squarepoint’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Squarepoint’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-95,332
Closed -$214K – 3736
2021
Q4 		$214K Buy
95,332
+42,473
+80% +$107K ﹤0.01% 2660
2021
Q3 		$181K Sell
52,859
-46,257
-47% -$143K ﹤0.01% 2530
2021
Q2 		$296K Buy
+99,116
New +$314K ﹤0.01% 2541
2018
Q1 		– Sell
-23,560
Closed -$48K – 2270
2017
Q4 		$48K Sell
23,560
-92,200
-80% -$191K ﹤0.01% 2020
2017
Q3 		$154K Buy
115,760
+101,634
+719% +$126K ﹤0.01% 1450
2017
Q2 		$22K Buy
+14,126
New +$27.2K ﹤0.01% 1488
2017
Q1 		– Sell
-54,830
Closed -$74K – 1998
2016
Q4 		$74K Buy
54,830
+36,330
+196% +$47.4K ﹤0.01% 1667
2016
Q3 		$29K Sell
18,500
-25,190
-58% -$38.7K ﹤0.01% 978
2016
Q2 		$58K Sell
43,690
-23,410
-35% -$109K ﹤0.01% 1019
2016
Q1 		$354K Buy
67,100
+13,200
+24% +$80.8K 0.03% 760
2015
Q4 		$423K Buy
+53,900
New +$464K 0.05% 621
2015
Q3 		– Sell
-10,400
Closed -$114K – 616
2015
Q2 		$114K Buy
+10,400
New +$133K 0.04% 399

Other funds holding INFI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GC
Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Squarepoint's INFI Position: Q1 2022 in Review

Squarepoint sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2022, closing a stake of 95,332 shares — an estimated $214K sold.

Squarepoint first reported a position in INFI in Q2 2015 and held it in 12 quarters. The position peaked at $423K in Q4 2015. 93 funds tracked by Wall St. Rank hold INFI as of Q1 2022.

  • Squarepoint reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
  • Squarepoint sold 95,332 Infinity Pharmaceuticals, Inc. shares in Q1 2022, an estimated $214K.
  • Squarepoint first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2015 and held it in 12 quarters.
  • Squarepoint's Infinity Pharmaceuticals, Inc. position peaked at $423K in Q4 2015.
  • 93 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2022.

Based on Squarepoint's 13F filing for Q1 2022, filed 16 May 2022.